Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study have?
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study has 183 citations in the OpenAlex counts ScholarIQ stores.
When was Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study published?
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study has 2019 year in the ScholarIQ index.
What is the open-access status of Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study?
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study has bronze oa status in the ScholarIQ index.
What is the DOI of Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study?
The DOI for Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study is on the source record.
What is the PMID of Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study?
The PMID for Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study is on the source record.
What is the OpenAlex record for Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study?
The OpenAlex for Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study is on the source record.